Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | MITF | O75030 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | GMNN | O75496 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kinetin Riboside SCHEMBL217034 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL17825970 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL29564117 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL3190252 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL14713232 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL3190271 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL19583061 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| Kinetin Riboside SCHEMBL14713468 | 1.00 | ADORA3 (1.00) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| SCHEMBL25170466 | 0.99 | ADORA3 (0.98) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 | |
| SCHEMBL29697393 | 0.99 | ADORA3 (0.98) | ADORA3SLC29A1TP53PAX8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126991-A1 | ADENOSINE DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021048235-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20150004696-A1 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2015-01-01 | — | — | US | disclosed |
| US-8822440-B2 | Inhibiting cyclin D polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-09-02 | — | — | US | disclosed |
| US-20100144685-A1 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2010-06-10 | — | — | US | disclosed |
| WO-2008045955-A9 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008045955-A2 | INHIBITING CYCLIN D POLYPEPTIDES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| EP-0355825-A2 | Viral treatment system | Prendergast, Patrick T. (IE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174033-B2 | N6-substituted adenosine derivatives and N6-substituted adenine derivatives and uses thereof | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885SLC29A1 267/4885TP53 3945/4885 |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | ADORA3 1717/4885SLC29A1 631/4885TP53 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.